Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $498.91, for a total transaction of $4,739,645.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares in the company, valued at approximately $161,867,857.13. This trade represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

United Therapeutics Stock Performance

United Therapeutics stock traded up $8.75 during trading hours on Monday, hitting $508.48. 457,341 shares of the stock were exchanged, compared to its average volume of 492,745. The stock has a market capitalization of $21.81 billion, a P/E ratio of 18.19, a P/E/G ratio of 1.69 and a beta of 0.59. United Therapeutics Corporation has a 12 month low of $302.19 and a 12 month high of $609.35. The business’s 50-day moving average is $535.95 and its two-hundred day moving average is $536.15.

Get United Therapeutics alerts:

United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. During the same quarter last year, the business posted $6.41 earnings per share. The company’s revenue was down 1.9% on a year-over-year basis. On average, equities analysts predict that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

Analysts Set New Price Targets

UTHR has been the subject of several research analyst reports. Bank of America cut their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Royal Bank Of Canada lowered their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. JPMorgan Chase & Co. upped their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Finally, Morgan Stanley set a $515.00 target price on shares of United Therapeutics in a research note on Thursday, August 6th. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $646.00.

View Our Latest Report on UTHR

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in UTHR. Torren Management LLC acquired a new position in shares of United Therapeutics during the fourth quarter valued at $26,000. Activest Wealth Management increased its position in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares during the period. Fiduciary Financial Advisors bought a new stake in United Therapeutics during the 2nd quarter worth about $30,000. WealthCollab LLC lifted its position in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the period. Finally, Rakuten Securities Inc. lifted its position in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares during the period. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

(Get Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

Featured Stories

• Five stocks we like better than United Therapeutics
• Commodities Are Booming, But These 3 ETFs Tell Different Stories
• 3 Active ETFs Making Big Moves in August
• This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
• Birkenstock Beats the Skeptics—But Not on EPS

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.